Flowchart of sampling strategy of concessions in each village.

<p>Flowchart of sampling strategy of concessions in each village.</p

Comparison of socio-demographic characteristics of 4792 individuals who consented to the serological (n = 3609) and screening- only (n = 1183) component of a study conducted in 60 villages of Burkina Faso in 2011–2012.

<p>Comparison of socio-demographic characteristics of 4792 individuals who consented to the serological (n = 3609) and screening- only (n = 1183) component of a study conducted in 60 villages of Burkina Faso in 2011–2012.</p

Univariate association between potential individual-level risk factors and the prevalence of current infection with cysticercosis among 3609 individuals providing serum in 60 villages of Burkina Faso, 2011–2012.

<p>Univariate association between potential individual-level risk factors and the prevalence of current infection with cysticercosis among 3609 individuals providing serum in 60 villages of Burkina Faso, 2011–2012.</p

Correlations between the village-level prevalence of current infection with cysticercosis and village-level variables in 60 villages of Burkina Faso, 2011–2012.

<p>Correlations between the village-level prevalence of current infection with cysticercosis and village-level variables in 60 villages of Burkina Faso, 2011–2012.</p

Additional file 1: of High prevalence of hepatitis B infections in Burkina Faso (1996–2017): a systematic review with meta-analysis of epidemiological studies

Method of meta-analysis. The document contains the calculation of meta-analysis. (PDF 268 kb

Location of the 60 participating villages in three Provinces of Burkina Faso.

<p>The estimated village prevalence of human cysticercosis for the 60 villages is presented in color-coded circles.</p

Prevalence odds ratios (95% Bayesian Credible Interval) of individual and village-level variables associated with the prevalence of current infection in 60 villages of Burkina Faso (2011–2012) from three hierarchical Bayesian hierarchical logistic models.

<p>Prevalence odds ratios (95% Bayesian Credible Interval) of individual and village-level variables associated with the prevalence of current infection in 60 villages of Burkina Faso (2011–2012) from three hierarchical Bayesian hierarchical logistic models.</p

Village-level seroprevalence of current infection with cysticercosis among 3609 individuals living in 60 villages of Burkina Faso, 2011–2012.

<p>Blue diamonds: Boulkiemdé, red diamonds: Nayala; green diamonds: Sanguié</p

Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of <i>Pfcrt</i> and <i>Pfmdr1</i> Alleles in Nanoro, Burkina Faso

<div><p>The adoption of Artemisinin based combination therapies (ACT) constitutes a basic strategy for malaria control in sub-Saharan Africa. Moreover, since cases of ACT resistance have been reported in South-East Asia, the need to understand <i>P</i>. <i>falciparum</i> resistance mechanism to ACT has become a global research goal. The selective pressure of ACT and the possibility that some specific <i>Pfcrt</i> and <i>Pfmdr1</i> alleles are associated with treatment failures was assessed in a clinical trial comparing ASAQ to AL in Nanoro. Dried blood spots collected on Day 0 and on the day of recurrent parasitaemia during the 28-day follow-up were analyzed using the restriction fragments length polymorphism (PCR-RFLP) method to detect single nucleotide polymorphisms (<i>SNPs</i>) in <i>Pfcrt</i> (codon76) and <i>Pfmdr1</i> (codons 86, 184, 1034, 1042, and 1246) genes. Multivariate analysis of the relationship between the presence of <i>Pfcrt</i> and <i>Pfmdr1</i> alleles and treatment outcome was performed. AL and ASAQ exerted opposite trends in selecting <i>Pfcrt K76T</i> and <i>Pfmdr1-N86Y</i> alleles, raising the potential beneficial effect of using diverse ACT at the same time as first line treatments to reduce the selective pressure by each treatment regimen. No clear association between the presence of <i>Pfcrt</i> and <i>Pfmdr1</i> alleles carried at baseline and treatment failure was observed.</p></div

Trial profile.

<p>The figure shows the number of isolates analyzed at day 0 and on the Day of recurrent parasitaemia (recrudescence and new infections) by treatment group (AL and ASAQ) and the number of successful PCR-RFLP amplification.</p